Premium
CD30‐CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR THERAPY OF HODGKIN LYMPHOMA (HL)
Author(s) -
Ramos C.A.,
Torrano V.,
Bilgi M.,
Gerken C.,
Dakhova O.,
Mei Z.,
Wu M.,
Grilley B.,
Gee A.P.,
Rooney C.M.,
Dotti G.,
Savoldo B.,
Heslop H.E.,
Brenner M.K.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.125_2629
Subject(s) - brentuximab vedotin , cd30 , medicine , chimeric antigen receptor , lymphoma , antigen , monoclonal antibody , cancer research , immunology , oncology , immunotherapy , antibody , immune system
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom